All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis is paying Kyorin $55 million upfront for exclusive global rights to develop, manufacture and commercialize KRP-M223, a preclinical mast-cell-targeting candidate for chronic spontaneous ...
Novartis is spending $55 million on global rights to Kyorin Pharmaceutical’s preclinical drug for inflammatory diseases in a deal that comes almost two ...
said David Soergel, M.D., Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. “Building on our longstanding expertise in nephrology and recent advancements in kidney diseases ...
ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...
Novartis AG failed to show that it will suffer harm from a Missouri law that requires it to discount drugs to an unlimited number of pharmacies under the 340B Drug Pricing Program, a federal judge ...
ZURICH, Feb 25 (Reuters) - Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 ...
Sorry, there were no product categories that matched your search term. To improve our service and ensure this does not happen in the future, please take a moment to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback